Monte Rosa Therapeutics (GLUE) Metrics: History & Chart

Monte Rosa Therapeutics, Inc.(GLUE)

Biotechnology · Boston, MA

$10.17-0.10 (-0.98%)

Delayed quote: Oct 6, 2026, 12:15 PM EDT

About Monte Rosa Therapeutics, Inc.

Monte Rosa Therapeutics, Inc. is a biopharmaceutical company dedicated to pioneering novel, small-molecule precision medicines. Their core approach involves leveraging the body's inherent mechanisms to precisely eliminate therapeutically relevant proteins. Among their key initiatives is an oral molecular glue degrader designed to target GSPT1, a specific translational termination factor and degron-containing protein, with the aim of treating Myc-driven cancers. The company's pipeline further includes programs for CDK2 in ovarian, uterine, and breast cancers, alongside NEK7 for addressing a spectrum of inflammatory conditions such as Crohn's disease, neurodegenerative ailments, diabetes, and liver disease. Moreover, VAV1 is being explored as a target for autoimmune disorders, and BCL11A, a protein holding significant therapeutic relevance, is under investigation for hemoglobinopathies. Founded in 2019, Monte Rosa Therapeutics, Inc. operates from its headquarters in Boston, Massachusetts.

Boston, MA

173 employees

www.monterosatx.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Markus Warmuth

View full financials

Third-Party DCF Estimate (FMP)	$30.87
Price Gap vs Third-Party Estimate	+200.56%

7D Total Return	-12.30%
30D Total Return	-25.79%
YTD Total Return	-34.50%
1Y Total Return	+32.69%
3Y Total Return	+125.73%
5Y Total Return	-48.17%
10Y Total Return	N/A
15Y Total Return	N/A
20Y Total Return	N/A

2026	-34.50%
2025	+125.94%
2024	+22.83%
2023	-25.76%
2022	-62.73%
2021	N/A

CAGR TTM	+32.51%
CAGR 3Y	+31.17%
CAGR 5Y	-12.32%
CAGR 10Y	N/A
CAGR 15Y	N/A
CAGR 20Y	N/A

PE Ratio	106.87
PE Ratio Avg TTM	76.88
PE Ratio Avg 3Y	76.88
Current VS TTM Avg	+39.02%
Current VS 3Y Avg	+39.02%
Current VS 5Y Avg	+39.02%

All Metrics

GLUE Valuation Metrics

GLUE Stock Price Metrics

GLUE Dividend Metrics

GLUE Growth Rate Metrics

GLUE Discounted Cash Flow Metrics

GLUE Returns By Period

GLUE Yearly Returns

GLUE Average Annual Returns By Period (CAGR)

GLUE Revenue Metrics

GLUE PE Ratio Metrics

GLUE PS Ratio Metrics

GLUE PB Ratio Metrics

GLUE Price to Free Cash Flow Ratio Metrics

GLUE Debt to Equity Ratio Metrics

GLUE PEG Ratio Metrics

GLUE FCF Yield

GLUE Earnings Yield

GLUE EBITDA Yield

GLUE OCF Yield

GLUE EV/EBIT Ratio Metrics

GLUE EV/EBITDA Ratio Metrics

GLUE EV/Assets Ratio Metrics

GLUE EV/Sales Ratio Metrics

GLUE Current Ratio Metrics

GLUE Quick Ratio Metrics

GLUE ROIC Metrics

GLUE Return on Assets Metrics

GLUE Return on Equity Metrics

GLUE Net Profit Margin Metrics

GLUE Gross Profit Margin Metrics

GLUE Tax Rate Metrics

PS Ratio	30.47
PS Ratio Avg TTM	20.29
PS Ratio Avg 3Y	24.30
Current VS TTM Avg	+50.20%
Current VS 3Y Avg	+25.40%
Current VS 5Y Avg	+25.40%

PB Ratio	1.80
PB Ratio Avg TTM	3.75
PB Ratio Avg 3Y	2.29
Current VS TTM Avg	-51.99%
Current VS 3Y Avg	-21.37%
Current VS 5Y Avg	-2.42%

PFCF Ratio	6.83
PFCF Ratio Avg TTM	10.50
PFCF Ratio Avg 3Y	10.50
Current VS TTM Avg	-34.97%
Current VS 3Y Avg	-34.97%
Current VS 5Y Avg	-34.97%

Debt/Equity Ratio	0.08
Debt/Equity Ratio Avg TTM	0.13
Debt/Equity Ratio Avg 3Y	0.19
Current VS TTM Avg	-38.88%
Current VS 3Y Avg	-58.06%
Current VS 5Y Avg	-47.51%

PEG Ratio	N/A
PEG Ratio Avg TTM	N/A
PEG Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

FCF Yield	14.64%
FCF Yield Avg TTM	10.05%
FCF Yield Avg 3Y	10.05%
Current VS TTM Avg	+45.68%
Current VS 3Y Avg	+45.68%
Current VS 5Y Avg	+45.68%

Earnings Yield	0.94%
Earnings Yield Avg TTM	1.60%
Earnings Yield Avg 3Y	1.60%
Current VS TTM Avg	-41.07%
Current VS 3Y Avg	-41.07%
Current VS 5Y Avg	-41.07%

EBITDA Yield	N/A
EBITDA Yield Avg TTM	N/A
EBITDA Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

OCF Yield	N/A
OCF Yield Avg TTM	N/A
OCF Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Ev/Ebit Ratio	96.62
Ev/Ebit Ratio Avg TTM	76.83
Ev/Ebit Ratio Avg 3Y	76.83
Current VS TTM Avg	+25.75%
Current VS 3Y Avg	+25.75%
Current VS 5Y Avg	+25.75%

Ev/Ebitda Ratio	48.83
Ev/Ebitda Ratio Avg TTM	45.75
Ev/Ebitda Ratio Avg 3Y	45.75
Current VS TTM Avg	+6.74%
Current VS 3Y Avg	+6.74%
Current VS 5Y Avg	+6.74%

Ev/Assets Ratio	1.18
Ev/Assets Ratio Avg TTM	2.03
Ev/Assets Ratio Avg 3Y	1.33
Current VS TTM Avg	-41.88%
Current VS 3Y Avg	-11.06%
Current VS 5Y Avg	+4.23%

Ev/Sales Ratio	28.65
Ev/Sales Ratio Avg TTM	18.85
Ev/Sales Ratio Avg 3Y	21.46
Current VS TTM Avg	+51.99%
Current VS 3Y Avg	+33.52%
Current VS 5Y Avg	+33.52%

Current Ratio	9.52
Current Ratio Avg TTM	7.78
Current Ratio Avg 3Y	6.80
Current VS TTM Avg	+22.48%
Current VS 3Y Avg	+40.11%
Current VS 5Y Avg	+3.59%

Quick Ratio	9.52
Quick Ratio Avg TTM	7.78
Quick Ratio Avg 3Y	6.80
Current VS TTM Avg	+22.48%
Current VS 3Y Avg	+40.11%
Current VS 5Y Avg	+3.59%

ROIC	(28.69%)
ROIC Avg 3Y	(31.82%)
ROIC Avg 5Y	(29.80%)
Current VS 3Y Avg	+9.83%
Current VS 5Y Avg	+3.72%
Current VS 10Y Avg	+2.35%

ROA	(23.15%)
ROA Avg TTM	(6.37%)
ROA Avg 3Y	(8.88%)
Current VS TTM Avg	-263.21%
Current VS 3Y Avg	-160.79%
Current VS 5Y Avg	-183.12%

ROE	(33.06%)
ROE Avg TTM	(11.40%)
ROE Avg 3Y	(38.34%)
Current VS TTM Avg	-189.93%
Current VS 3Y Avg	+13.77%
Current VS 5Y Avg	+5.48%

Net Profit Margin	(560.85%)
Net Profit Margin Avg TTM	(693.01%)
Net Profit Margin Avg 3Y	(239.38%)
Current VS TTM Avg	+19.07%
Current VS 3Y Avg	-134.29%
Current VS 5Y Avg	-540.51%

Gross Profit Margin	92.94%
Gross Pft Margin Avg TTM	90.36%
Gross Pft Margin Avg 3Y	56.13%
Current VS TTM Avg	+2.85%
Current VS 3Y Avg	+65.59%
Current VS 5Y Avg	+167.49%

Tax Rate	1.72%
Tax Rate Avg 3Y	7.80%
Tax Rate Avg 5Y	7.80%
Current VS 3Y Avg	-77.90%
Current VS 5Y Avg	-77.90%
Current VS 10Y Avg	-77.90%